Chart Of The Day: Uncertain Outlook For Pfizer Could See Stock Slide To $30
Investing.com | Nov 07, 2022 13:25
Pfizer (NYSE:PFE) faces a $16 to $18 billion loss in revenue from 2025 through 2030 as it loses essential patents on five drugs.
The drugs account for 40% of the company's Q3 revenue when its COVID vaccine and antiviral treatment, Paxlovid are excluded. The five drugs are -Eliquis to prevent blood clots, Vyndaqel for cardiomyopathy, Xeljanz for rheumatoid arthritis, Ibrance for breast cancer and Xtandi for prostate cancer.
It is also worth noting that the future of the coronavirus is unclear. If it subsides, it will hit demand for Paxlovid and COVID vaccines which accounted for 52% of revenue for the quarter.
CEO Albert Bourla plans to deal with these future losses by generating revenue from its recent acquisitions, leveraging its in-house drugs and vaccine pipeline as well as focusing on respiratory syncytial virus, migraines, and ulcerative colitis.
However, based on the current chart it seems investors are not convinced about the strategy.
The stock has completed a cross between a descending and a symmetrical triangle. Although the descending variety is a more transparent presentation of supply overtaking demand, once there is a breakout, technicians expect the same technical chain reaction to follow both.
Note the rising volume accompanying the downside breakout and the dead drop in that participation when the price rebounds.
I would have preferred a sharper spike as the pattern completed, but bears may feel that the sparse volume of the return move compensates, showing an obvious negative divergence.
Still, the price found resistance by the bottom of the triangle which confirms the overselling within the pattern, and the 200-day moving average is a rational bullish stronghold.
Target/h2
Measure the pattern's height and deduct that figure from the breakout point. The assumption is that the same interest that dominated the price structure will maintain its struggle below it, therefore repeating the $16.31 move from $46.82 to $30.51.
Trading Strategies/h2
Conservative traders should wait for confirmation that resistance persists, such as with a long red candle, before risking a short.
Moderate traders would be content with a weekly close below the pattern.
Aggressive traders could short at will, according to their strategy, incorporating their timing, budget, and temperament. Here is a generic example:
Trade Sample - Aggressive Short Position
- Entry: $47
- Stop-Loss: $50
- Risk: $3
- Target: $38
- Reward: $9
- Risk-Reward Ratio: 1:3
Get The App
Disclaimer: At the time of publication, the author had no positions in the securities mentioned.
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.